Caroline M. Loewy - 18 Jan 2022 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Reporting relationship: Director
Issuer ticker: APTOF
Reported as of: 18 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jan 2022, 16:13:14 UTC
Prior SEC filing: 12 Oct 2021
Next SEC filing: 27 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Janet Clennett as attorney-in-fact for Caroline M. Loewy

Key filing fact

Caroline M. Loewy filed Form 4 for Aptose Biosciences Inc. (APTOF) on 20 Jan 2022.

Key facts

This page summarizes Caroline M. Loewy's Form 4 filing for Aptose Biosciences Inc. (APTOF).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jan 2022, 16:13.

Change

Previous filing in this sequence was filed on 12 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APTO transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 18 Jan 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $1.34
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on January 18, 2022, and vest as follows: 50% vest on January 18, 2023; 25% vest on January 18, 2024; and 25% vest on January 18, 2025.